Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Pulmonary Arterial Hypertension (PAH)
Interventions
DRUG

Treprostinil

Treprostinil is initiated at a dose of 1.25 ng/kg/min. The dose is then titrated upwards based on individual patient tolerability and clinical response. The planned titration schedule is an increase of 1.25 ng/kg/min weekly for the first four weeks of treatment, followed by weekly increases of 2.5 ng/kg/min thereafter, as tolerated.

All Listed Sponsors
lead

Shanghai Zhongshan Hospital

OTHER

NCT07177703 - Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter